Vincent A. Miller
Foundation Medicine
CancerPathologyCancer researchMedicineBiology
What is this?
Publications 933
#1Mary W. Redman (Fred Hutchinson Cancer Research Center)H-Index: 25
Last. Natasha B. Leighl (Princess Margaret Cancer Centre)H-Index: 48
view all 19 authors...
#1Brittany Siontis (UM: University of Michigan)H-Index: 1
#2Jonathan B. McHugh (UM: University of Michigan)H-Index: 32
Last. Yi-Mi Wu (UM: University of Michigan)H-Index: 6
view all 14 authors...
#1Ethan Sokol (Foundation Medicine)H-Index: 3
#2Dean Pavlick (Foundation Medicine)H-Index: 9
Last. Andrea NecchiH-Index: 23
view all 15 authors...
PURPOSEBRCA1 or BRCA2 loss of function results in homologous recombination deficiency (HRD), which is targetable by poly (ADP-ribose) polymerase (PARP) inhibitors and other DNA-damaging agents. In ...
: Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient's tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.
BACKGROUND: Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify potential molecular explanations for responses. METHODS: Exceptional response was d...
#1Alexa B. SchrockH-Index: 20
#2Russell MadisonH-Index: 3
view all 16 authors...
Background: ALK fusions are targetable drivers in non-small-cell lung cancer (NSCLC). However, patients with NSCLC harboring ALK rearrangements without a fusion partner identified in DNA have also been shown to respond to ALK inhibitors. We aimed to characterize complex ALK variants that may predict sensitivity to multiple approved ALK inhibitors. Methods: Comprehensive genomic profiling (CGP) of DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue or blood-based circulating tu...
#1Margaret A. Hay (OSU: Ohio State University)
#2Eric Allan Severson (Foundation Medicine)H-Index: 4
Last. James L. Chen (OSU: Ohio State University)H-Index: 8
view all 7 authors...
PURPOSEComprehensive genomic profiling (CGP) of sarcomas is rapidly being integrated into routine clinical care to help refine diagnosis and prognosis and determine treatment. However, little is kn...
#1Ariella B. Hanker (UTSW: University of Texas Southwestern Medical Center)H-Index: 9
#2Harikrishna Sekar Jayanthan (Vandy: Vanderbilt University)
Last. Alberto Servetto (UTSW: University of Texas Southwestern Medical Center)H-Index: 6
view all 15 authors...
Activating mutations in HER2 (ERBB2) drive the growth of a subset of breast cancers. The HER2 tyrosine kinase inhibitor (TKI) neratinib has shown clinical activity against cancers harboring HER2 activating mutations. Co-occurring HER2 and HER3 (ERBB3) mutations have been reported to co-occur in patients with breast cancer, suggesting the possibility of cooperativity of both oncogenes. Interrogation of the Project GENIE database revealed that gain-of-function missense mutations in HER2 and HER3 e...
#1Erik A. WilliamsH-Index: 2
#1Erik A. WilliamsH-Index: 5
Last. Vincent A. MillerH-Index: 45
view all 11 authors...
#1Amanda Hemmerich (Foundation Medicine)H-Index: 1
#2Claire Edgerly (Foundation Medicine)H-Index: 1
Last. Douglas I. Lin (Foundation Medicine)H-Index: 15
view all 20 authors...
757Background: Pancreas ductal adenocarcinomas (PDA) has a 5-year survival rate of 6% with a need for new therapeutic options. The approval of pembrolizumab for some gastrointestinal cancers shows ...